Location out of bounds
Technician conducting lab tests

Molecular Oncology

Innovative diagnostic and prognostic testing in blood cancers. Learn more about our NEW FLT3 Companion Diagnostic.

Order Now

Client Services

Email 800-245-3117 x 6250 Request Information Online Ordering Portal Forms & Requisitions Accreditations and Licenses

Versiti continues to innovate and add to our test menu, helping physicians offer patients superior treatment options.


Versiti offers all the companion diagnostic tests that can aid in identifying acute myeloid leukemia (AML) patients at diagnosis and/or relapse. Patients with IDH1 and IDH2 mutations may be treated with the FDA-approved drugs ivosidenib (TIBSOVO®) and enasidenib (IDHIFA®). Patients with FLT3 mutations may be treated with FDA-approved drugs midostaurin (RYDAPT®) and gilteritinib (XOSPATA®).

The value of molecular oncology testing from Versiti

  • Don’t wait for precision laboratory medicine. Since the launch of both IDH assays in August 2018, Versiti has rapidly reported test results within an average of four days.
  • Identify more patients who could benefit from new targeted therapies. IDH Abbott tests have high detection rates, down to 1% mutational burden as documented in FDA submissions.
  • The LeukoStrat FLT3 test is the only internationally standardized quantitative test for both ITD and TKD mutations.

NEW! LeukoStrat CDx FLT3 Mutation Assay (Test Code: 4675)

This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an FLT3 mutation for treatment with FDA-approved drugs midostaurin (RYDAPT®) and gilteritinib (XOSPATA®). Learn more.

NEW! IDH1 Abbott Realtime PCR test (Test Code: 7647)

This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib). Learn More.

NEW! IDH2 Abbott Realtime PCR test (Test Code: 7648)

This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFA® (enasidenib). Learn More.

Versiti provides innovative diagnostic and prognostic testing in blood cancers to support patient stratification and therapeutic decisions. We deliver novel testing services that provide critical clinical direction in complex cases of acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and chronic myelogenous leukemia (CML). Our testing menus are built around testing algorithms as recommended by the National Comprehensive Cancer Network (NCCN) and the World Health Organization (WHO).

View Our Complete Diagnostic Lab Catalog

ic-arrow-right
x

This website uses cookies to ensure you get the best experience on our website. Learn more